Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.13 -0.3%	$3.30	$2.71 ▼ $4.73	$599.48M	1.2	951,088 shs	894,105 shs
CGC Canopy Growth	$1.09 -1.8%	$1.39	$0.77 ▼ $8.65	$200.41M	0.73	6.61 million shs	4.60 million shs
PRTA Prothena	$6.26 -3.2%	$6.02	$4.32 ▼ $25.42	$336.96M	0.01	808,155 shs	788,135 shs
REPL Replimune Group	$12.09 -3.3%	$9.53	$6.44 ▼ $17.00	$931.98M	0.61	947,958 shs	3.35 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-0.32%	-1.26%	-9.80%	-0.63%	-17.20%
CGC Canopy Growth	-1.80%	-3.54%	-15.50%	-8.40%	-85.37%
PRTA Prothena	-3.25%	-2.19%	+8.87%	-31.96%	-73.78%
REPL Replimune Group	-3.28%	+10.21%	+27.40%	+51.31%	+13.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.566 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.6
CGC Canopy Growth	0.481 of 5 stars	0.0	2.0	0.0	2.7	0.0	1.3
PRTA Prothena	3.3866 of 5 stars	4.2	4.0	0.0	0.6	1.7	1.3
REPL Replimune Group	4.1214 of 5 stars	3.6	1.0	4.5	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	75.72% Upside
CGC Canopy Growth	1.00	Sell	N/A	N/A
PRTA Prothena	2.33	Hold	$31.50	403.19% Upside
REPL Replimune Group	3.13	Buy	$21.00	73.70% Upside

Current Analyst Ratings Breakdown

Latest CGC, PRTA, REPL, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$16.00 ➝ $19.00
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	97.16	N/A	N/A	$0.51 per share	6.14
CGC Canopy Growth	$225.65M	0.89	N/A	N/A	$1.90 per share	0.57
PRTA Prothena	$135.16M	2.49	N/A	N/A	$9.05 per share	0.69
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
CGC Canopy Growth	-$429.86M	-$4.04	N/A	N/A	N/A	-195.76%	-88.54%	-40.78%	8/8/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)

Latest CGC, PRTA, REPL, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PRTA Prothena	-$1.06	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q1 2026	REPL Replimune Group	-$0.85	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.10	N/A	N/A	N/A	$64.98 million	N/A
8/7/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	N/A	N/A	N/A	N/A	N/A
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
CGC Canopy Growth	0.62	3.12	2.10
PRTA Prothena	N/A	9.00	9.00
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CGC Canopy Growth	3.33%
PRTA Prothena	97.08%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CGC Canopy Growth	1.30%
PRTA Prothena	9.20%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
CGC Canopy Growth	3,150	183.87 million	181.48 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

CGC, PRTA, REPL, and ABUS Headlines

Recent News About These Companies

Replimune Group (NASDAQ:REPL) Stock Price Down 5.2% - Here's What Happened

July 19 at 2:38 PM | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

July 18 at 4:05 AM | americanbankingnews.com

Investors Purchase High Volume of Call Options on Replimune Group (NASDAQ:REPL)

July 17 at 3:39 AM | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst Upgrade

July 17 at 2:27 AM | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Shares Gap Up on Analyst Upgrade

July 16 at 10:34 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Price Target Raised to $19.00 at JPMorgan Chase & Co.

July 16 at 8:37 AM | marketbeat.com

Replimune Group (NASDAQ:REPL) Trading Up 5.7% - Time to Buy?

July 15, 2025 | marketbeat.com

Replimune Group Target of Unusually High Options Trading (NASDAQ:REPL)

July 15, 2025 | marketbeat.com

Replimune Announces Inducement Grants Under Nasdaq ... - Morningstar

July 13, 2025 | morningstar.comM

Replimune Group, Inc. (REPL) Stock Competitors & Similar Stocks ...

July 12, 2025 | seekingalpha.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Up 4.4% - Should You Buy?

July 7, 2025 | marketbeat.com

Moody Aldrich Partners LLC Makes New $1.93 Million Investment in Replimune Group, Inc. (NASDAQ:REPL)

July 4, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Earns "Buy" Rating from HC Wainwright

July 3, 2025 | marketbeat.com

Replimune Group, Inc. (REPL) - Yahoo Finance

July 1, 2025 | finance.yahoo.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

June 25, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight Recommendation

June 20, 2025 | msn.com

Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

June 20, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.comQ

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?

CGC, PRTA, REPL, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.13 -0.01 (-0.32%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.16 +0.03 (+0.96%)

As of 07/18/2025 07:25 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Canopy Growth NASDAQ:CGC

$1.09 -0.02 (-1.80%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.09 +0.00 (+0.09%)

As of 07/18/2025 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Prothena NASDAQ:PRTA

$6.26 -0.21 (-3.25%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.64 +0.38 (+6.07%)

As of 07/18/2025 07:33 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Replimune Group NASDAQ:REPL

$12.09 -0.41 (-3.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$12.23 +0.14 (+1.16%)

As of 07/18/2025 07:59 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time